Aura Biosciences Secures $299M in Public Offering, Underwriters Fully Exercise Option
AURA sits 97% above its 52-week low of $4.345 on elevated volume (15× avg).
Summary
Aura Biosciences announced the closing of its public offering, raising approximately $299 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase additional shares, with common stock priced at $6.00 per share and pre-funded warrants at $5.99999. This closing follows a series of recent filings and news regarding a proposed public offering, including a 424B5 on May 4th that reported the finalization of an offering to raise $244.7 million. The current announcement confirms the closing and indicates a higher final capital raise due to the full exercise of the underwriters' option. The $299 million capital raise is highly significant, representing over 50% of the company's current market capitalization, providing a critical extension to the company's cash runway and addressing the going concern warning highlighted in its last 10-K. Investors will now focus on how this capital is deployed to advance its clinical development programs, particularly the Phase 3 CoMpass trial for bel-sar.
At the time of this announcement, AURA was trading at $8.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $571.4M. The 52-week trading range was $4.35 to $9.54. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.